You are here: Home » Reuters » News
Business Standard

Takeda sees lower annual profit, generics to erode cancer drug sales

Reuters  |  TOKYO 

By Sam NusseyTOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent drop in operating profit for the year through March 2019 as blood cancer drug Velcade looks set to face generic competition in the United States.The loss of Velcade's exclusivity will be partly offset by growing sales of bowel disease treatment Entyvio and heartburn and ulcer drug Takecab, but Takeda's lower overall profitability underscores the firm's need to bolster its drug pipeline. "It's always hard in a pharmaceutical company to synchronise your pipeline with your generic exposure," ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, May 14 2018. 17:04 IST